Mavacamten for Patients who have Failed Prior Advanced Therapy for LV Outflow Obstruction | After Alcohol Ablation, Surgery, Disopyramide and for LVOT Obstruction After AVR and TAVR

Sunday, March 9, 2025

4:12 PM – 4:20 PM ET

Speaker(s)

Daniele Massera, MD

Associate Director, Hypertrophic Cardiomyopathy Program
NYU Langone Health
New York, New York, United States

Disclosure(s): Chiesi: Consulting Fees (e.g., advisory boards) (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Cytokinetics: Consulting Fees (e.g., advisory boards) (Terminated); Sanofi: Consulting Fees (e.g., advisory boards) (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Tenaya Therapeutics: Consulting Fees (e.g., advisory boards) (Terminated)

Disclosure(s):

Daniele Massera, MD: Chiesi: Consulting Fees (e.g., advisory boards) (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Cytokinetics: Consulting Fees (e.g., advisory boards) (Terminated); Sanofi: Consulting Fees (e.g., advisory boards) (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Tenaya Therapeutics: Consulting Fees (e.g., advisory boards) (Terminated)